The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease

Tissue Barriers

Volumn 5, Issue 3, 2017, Pages

  Pothoven, Kathryn L ^a,b   Schleimer, Robert P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

epithelial barrier function; epithelial mesenchymal transition; neutrophil; Oncostatin M; type 2 inflammation

Indexed keywords

ARGINASE 1; CALVASCULIN; CD16 ANTIGEN; CORTICOSTEROID; FOLLISTATIN RELATED PROTEIN; HEAT SHOCK PROTEIN 47; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 4; NERVE CELL ADHESION MOLECULE; ONCOSTATIN M; OSTEOPONTIN; PROSTAGLANDIN E2; RANTES; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; GROWTH INHIBITOR;

ACTIN POLYMERIZATION; ADENOVIRUS INFECTION; ARTHRITIS; ASTHMA; BONE METABOLISM; CANCER GROWTH; CANCER PROGNOSIS; COLON CARCINOMA; CROHN DISEASE; DENDRITIC CELL; DIABETES MELLITUS; ENVIRONMENTAL EXPOSURE; EPIDERMIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM; GAIN OF FUNCTION MUTATION; HUMAN; INFLAMMATORY DISEASE; MAPK SIGNALING; NEUTROPHILIA; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; SKIN INJURY; ANIMAL; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; IMMEDIATE TYPE HYPERSENSITIVITY; METABOLISM; PATHOLOGY;

ANIMALS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH INHIBITORS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; ONCOSTATIN M;

EID: 85021624530     PISSN: 21688362     EISSN: 21688370     Source Type: Journal    
DOI: 10.1080/21688370.2017.1341367     Document Type: Review

References (167)

1. Podolsky DK. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair:the best offense is a good defense. Am J Physiol 1999; 277(3 Pt 1):G495-9; PMID:10484372
2. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998; 273(45):29745-53; PMID:9792688; https://doi.org/10.1074/jbc.273.45.29745
3. Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins initiate host defense. Adv Exp Med Biol 2007; 601:185-94; PMID:17713005
4. Porter RM, Lane EB. Phenotypes, genotypes and their contribution to understanding keratin function. Trends Genet 2003; 19(5):278-85; PMID:12711220; https://doi.org/10.1016/S0168-9525(03)00071-4
5. Avila PC, Schleimer RP. Airway Epithelium. Allergy and Allergic Diseases. Wiley-Blackwell 2009. p. 366-97
6. Casanova L, Bravo A, Were F, Ramirez A, Jorcano JJ, Vidal M. Tissue-specific and efficient expression of the human simple epithelial keratin 8 gene in transgenic mice. J Cell Sci 1995; 108(Pt 2):811-20; PMID:7539440
7. Staskowski PA, McCaffrey TV. Effect of substance P on ciliary beat frequency in human adenoid explants. Otolaryngol Head Neck Surg 1992; 107(4):553-7; PMID:1279501; https://doi.org/10.1177/019459989210700407
8. Albertine KH, Williams MC, Hyde DM. Anatomy and development of the repiratory tract. Murray JF, Nadel JA, Mason RJ, Boushey HA, editor. Philadelphia:W. B. Saunders; 2000
9. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001; (29):7-15; PMID:11694559; https://doi.org/10.1093/oxfordjournals.jncimonographs.a003443
10. Habif TP. Clinical Dermatology. 5th ed. Edinburgh:Mosby Elsevier; 2010
11. Ross MH, Kaye GI, Pawlina W. Histology:A Text and Atlas with Cell and Molecular Biology:Lippincott Williams & Wilkins. 2002
12. Neunlist M, Van Landeghem L, Mahe MM, Derkinderen P, des Varannes SB, Rolli-Derkinderen M. The digestive neuronal-glial-epithelial unit:a new actor in gut health and disease. Nat Rev Gastroenterol Hepatol 2013; 10(2):90-100; PMID:23165236; https://doi.org/10.1038/nrgastro.2012.221
13. Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Annu Rev Cell Dev Biol 2006; 22:207-35; PMID:16771626; https://doi.org/10.1146/annurev.cellbio.22.010305.104219
14. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006; 68:403-29; PMID:16460278; https://doi.org/10.1146/annurev.physiol.68.040104.131404
15. Mattagajasingh SN, Huang SC, Hartenstein JS, Benz EJ, Jr. Characterization of the interaction between protein 4.1R and ZO-2. A possible link between the tight junction and the actin cytoskeleton. J Biol Chem 2000; 275(39):30573-85; PMID:10874042; https://doi.org/10.1074/jbc.M004578200
16. Tsukita S, Yamazaki Y, Katsuno T, Tamura A, Tsukita S. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 2008; 27(55):6930-8; PMID:19029935; https://doi.org/10.1038/onc.2008.344
17. Lilien J, Balsamo J, Arregui C, Xu G. Turn-off, drop-out:functional state switching of cadherins. Dev Dyn 2002; 224(1):18-29; PMID:11984870; https://doi.org/10.1002/dvdy.10087
18. McGuire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 2003; 162(6):1831-43; PMID:12759241; https://doi.org/10.1016/S0002-9440(10)64318-0
19. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005; 17(5):459-65; PMID:16099633; https://doi.org/10.1016/j.ceb.2005.08.009
20. Nelson WJ, Dickinson DJ, Weis WI. Roles of cadherins and catenins in cell-cell adhesion and epithelial cell polarity. Prog Mol Biol Transl Sci 2013; 116:3-23; PMID:23481188
21. Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ. Deconstructing the cadherin-catenin-actin complex. Cell 2005; 123(5):889-901; PMID:16325582; https://doi.org/10.1016/j.cell.2005.09.020
22. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Eng J Med 2002; 346(22):1699-705; PMID:12037149; https://doi.org/10.1056/NEJMoa012705
23. Wardlaw AJ, Brightling CE, Green R, Woltmann G, Bradding P, Pavord ID. New insights into the relationship between airway inflammation and asthma. Clin Sci 2002; 103(2):201-11; PMID:12149112; https://doi.org/10.1042/cs1030201
24. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356(9248):2144-8; PMID:11191542; https://doi.org/10.1016/S0140-6736(00)03496-6
25. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients:results of two phase 2a studies. Lancet 2007; 370(9596):1422-31; PMID:17950857; https://doi.org/10.1016/S0140-6736(07)61600-6
26. Wenzel SE. Asthma phenotypes:the evolution from clinical to molecular approaches. Nat Med 2012; 18(5):716-25; PMID:22561835; https://doi.org/10.1038/nm.2678
27. Hackett TL, de Bruin HG, Shaheen F, van den Berge M, van Oosterhout AJ, Postma DS, Heijink IH. Caveolin-1 controls airway epithelial barrier function. Implications for asthma. Am J Respir Cell Mol Biol 2013; 49(4):662-71; PMID:23742006; https://doi.org/10.1165/rcmb.2013-0124OC
28. Hackett TL, Singhera GK, Shaheen F, Hayden P, Jackson GR, Hegele RG, Van Eeden S, Bai TR, Dorscheid DR, Knight DA. Intrinsic phenotypic differences of asthmatic epithelium and its inflammatory responses to respiratory syncytial virus and air pollution. Am J Respir Cell Mol Biol 2011; 45(5):1090-100; PMID:21642587; https://doi.org/10.1165/rcmb.2011-0031OC
29. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128(3):549-56 e1-12; PMID:21752437; https://doi.org/10.1016/j.jaci.2011.05.038
30. Grencis RK, Humphreys NE, Bancroft AJ. Immunity to gastrointestinal nematodes:mechanisms and myths. Immunol Rev 2014; 260(1):183-205; PMID:24942690; https://doi.org/10.1111/imr.12188
31. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, Tsai M, Galli SJ. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006; 313(5786):526-30; PMID:16873664; https://doi.org/10.1126/science.1128877
32. Qiu Y, Nguyen KD, Odegaard JI, Cui X, Tian X, Locksley RM, Palmiter RD, Chawla A. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 2014; 157(6):1292-308; PMID:24906148; https://doi.org/10.1016/j.cell.2014.03.066
33. Chu VT, Beller A, Rausch S, Strandmark J, Zanker M, Arbach O, Kruglov A, Berek C. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity 2014; 40(4):582-93; PMID:24745334; https://doi.org/10.1016/j.immuni.2014.02.014
34. Isobe Y, Kato T, Arita M. Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol 2012; 3:270; PMID:22973272; https://doi.org/10.3389/fimmu.2012.00270
35. Goldie RG, Fernandes LB, Rigby PJ, Paterson JW. Epithelial dysfunction and airway hyperreactivity in asthma. Prog Clin Biol Res 1988; 263:317-29; PMID:2898153
36. Heyman M, Desjeux JF. Cytokine-induced alteration of the epithelial barrier to food antigens in disease. Ann N Y Acad Sci 2000; 915:304-11; PMID:11193593; https://doi.org/10.1111/j.1749-6632.2000.tb05258.x
37. Tieu DD, Kern RC, Schleimer RP. Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. J Allergy Clin Immunol 2009; 124(1):37-42; PMID:19560577; https://doi.org/10.1016/j.jaci.2009.04.045
38. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Eng J Med 2011; 365(14):1315-27; PMID:21991953; https://doi.org/10.1056/NEJMra1011040
39. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127(3):773-86 e1-7; PMID:21163515; https://doi.org/10.1016/j.jaci.2010.10.018
40. Venkataraman D, Soto-Ramirez N, Kurukulaaratchy RJ, Holloway JW, Karmaus W, Ewart SL, Arshad SH, Erlewyn-Lajeunesse M. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol 2014; 134(4):876-82 e4; https://doi.org/10.1016/j.jaci.2014.07.033
41. Palmer CN, Ismail T, Lee SP, Terron-Kwiatkowski A, Zhao Y, Liao H, Smith FJ, McLean WH, Mukhopadhyay S. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007; 120(1):64-8; PMID:17531295; https://doi.org/10.1016/j.jaci.2007.04.001
42. Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, Ruether A, Klopp N, Vogelberg C, Weiland SK, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121(5):1203-9 e1; https://doi.org/10.1016/j.jaci.2008.02.014
43. Dale BA, Holbrook KA, Steinert PM. Assembly of stratum corneum basic protein and keratin filaments in macrofibrils. Nature 1978; 276(5689):729-31; PMID:732879; https://doi.org/10.1038/276729a0
44. Harding CR, Scott IR. Histidine-rich proteins (filaggrins):structural and functional heterogeneity during epidermal differentiation. J Mol Biol 1983; 170(3):651-73; PMID:6195345; https://doi.org/10.1016/S0022-2836(83)80126-0
45. Mocsai G, Gaspar K, Nagy G, Irinyi B, Kapitany A, Biro T, Gyimesi E, Tóth B, Maródi L, Szegedi A. Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis. Br J Dermatol 2014; 170(3):617-24; PMID:24251354; https://doi.org/10.1111/bjd.12743
46. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112(6 Suppl):S118-27; PMID:14657842; https://doi.org/10.1016/j.jaci.2003.09.033
47. Trejo Bittar HE, Yousem SA, Wenzel SE. Pathobiology of severe asthma. Annu Rev Pathol 2015; 10:511-45; PMID:25423350; https://doi.org/10.1146/annurev-pathol-012414-040343
48. Shah A, Kagalwalla AF, Gonsalves N, Melin-Aldana H, Li BU, Hirano I. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009; 104(3):716-21; PMID:19209168; https://doi.org/10.1038/ajg.2008.117
49. Rose TM, Bruce AG. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci U S A 1991; 88(19):8641-5; PMID:1717982; https://doi.org/10.1073/pnas.88.19.8641
50. Tamura S, Morikawa Y, Miyajima A, Senba E. Expression of oncostatin M in hematopoietic organs. Dev Dyn 2002; 225(3):327-31; PMID:12412016; https://doi.org/10.1002/dvdy.10156
51. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 1987; 139(9):2977-83
52. Salamon P, Shoham NG, Puxeddu I, Paitan Y, Levi-Schaffer F, Mekori YA. Human mast cells release oncostatin M on contact with activated T cells:possible biologic relevance. J Allergy Clin Immunol 2008; 121(2):448-55 e5; https://doi.org/10.1016/j.jaci.2007.08.054
53. Grove RI, Mazzucco C, Allegretto N, Kiener PA, Spitalny G, Radka SF, Shoyab M, Antonaccio M, Warr GA. Macrophage-derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells. J Lipid Res 1991; 32(12):1889-97; PMID:1816320
54. Scaffidi AK, Mutsaers SE, Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002; 136(5):793-801; PMID:12086989; https://doi.org/10.1038/sj.bjp.0704769
55. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, et al. The IL-6 signal transducer, gp130:an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255(5050):1434-7; PMID:1542794; https://doi.org/10.1126/science.1542794
56. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271(51):32635-43; PMID:8999038; https://doi.org/10.1074/jbc.271.51.32635
57. Ichihara M, Hara T, Kim H, Murate T, Miyajima A. Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood 1997; 90(1):165-73; PMID:9207450
58. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206(7):1465-72; PMID:19564350; https://doi.org/10.1084/jem.20082683
59. Soldi R, Graziani A, Benelli R, Ghigo D, Bosia A, Albini A, Bussolino F. Oncostatin M activates phosphatidylinositol-3-kinase in Kaposi's sarcoma cells. Oncogene 1994; 9(8):2253-60; PMID:8036010
60. Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, Krolewski JJ, Silvennoinen O, Saharinen P, Pierce J, et al. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 1997; 17(7):3833-40; PMID:9199317; https://doi.org/10.1128/MCB.17.7.3833
61. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994; 263(5143):89-92; PMID:8272872; https://doi.org/10.1126/science.8272872
62. Ernst M, Oates A, Dunn AR. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 1996; 271(47):30136-43; PMID:8939963; https://doi.org/10.1074/jbc.271.47.30136
63. Lamb P, Seidel HM, Haslam J, Milocco L, Kessler LV, Stein RB, Rosen J. STAT protein complexes activated by interferon-gamma and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties. Nucleic Acids Res 1995; 23(16):3283-9; PMID:7667105; https://doi.org/10.1093/nar/23.16.3283
64. Kuropatwinski KK, De Imus C, Gearing D, Baumann H, Mosley B. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. J Biol Chem 1997; 272(24):15135-44; PMID:9182534; https://doi.org/10.1074/jbc.272.24.15135
65. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 1992; 148(6):1731-6
66. Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells:role of cyclooxygenase-2. Clin Exp Metastasis 2004; 21(2):167-76; PMID:15168734; https://doi.org/10.1023/B:CLIN.0000024760.02667.db
67. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000; 157(4):1187-96; PMID:11021823; https://doi.org/10.1016/S0002-9440(10)64634-2
68. Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum 2009; 60(7):1932-43; PMID:19565514; https://doi.org/10.1002/art.24602
69. Malik N, Haugen HS, Modrell B, Shoyab M, Clegg CH. Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol 1995; 15(5):2349-58; PMID:7739518; https://doi.org/10.1128/MCB.15.5.2349
70. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ. Oncostatin M:a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986; 83(24):9739-43; PMID:3540948; https://doi.org/10.1073/pnas.83.24.9739
71. Beigel F, Friedrich M, Probst C, Sotlar K, Goke B, Diegelmann J, Brand S. Oncostatin M Mediates STAT3-Dependent Intestinal Epithelial Restitution via Increased Cell Proliferation, Decreased Apoptosis and Upregulation of SERPIN Family Members. PloS One 2014; 9(4):e93498; PMID:24710357; https://doi.org/10.1371/journal.pone.0093498
72. Ganesh K, Das A, Dickerson R, Khanna S, Parinandi NL, Gordillo GM, Sen CK, Roy S. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J Immunol 2012; 189(5):2563-73; https://doi.org/10.4049/jimmunol.1102762
73. Poling J, Gajawada P, Lorchner H, Polyakova V, Szibor M, Bottger T, Warnecke H, Kubin T, Braun T. The Janus face of OSM-mediated cardiomyocyte dedifferentiation during cardiac repair and disease. Cell Cycle 2012; 11(3):439-45; PMID:22262173; https://doi.org/10.4161/cc.11.3.19024
74. Glezer I, Rivest S. Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites. Brain Behav Immun 2010; 24(5):695-704; PMID:20083191; https://doi.org/10.1016/j.bbi.2010.01.005
75. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing:an update. J Dermatol 2001; 28(10):521-34; PMID:11732719; https://doi.org/10.1111/j.1346-8138.2001.tb00025.x
76. Jung ID, Noh KT, Lee CM, Chun SH, Jeong SK, Park JW, Park WS, Kim HW, Yun CH, Shin YK, et al. Oncostatin M induces dendritic cell maturation and Th1 polarization. Biochem Biophys Res Commun 2010; 394(2):272-8; PMID:20206608; https://doi.org/10.1016/j.bbrc.2010.02.153
77. Broxmeyer HE, Bruns HA, Zhang S, Cooper S, Hangoc G, McKenzie AN, Dent AL, Schindler U, Naeger LK, Hoey T, et al. Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. Immunity 2002; 16(6):815-25; PMID:12121663; https://doi.org/10.1016/S1074-7613(02)00319-9
78. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M:a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002; 46(4):961-7; PMID:11953973; https://doi.org/10.1002/art.10212
79. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC. Potential novel biomarkers of disease activity in rheumatoid arthritis patients:CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58(8):2257-67; PMID:18668547; https://doi.org/10.1002/art.23667
80. Le Goff B, Singbrant S, Tonkin BA, Martin TJ, Romas E, Sims NA, Walsh NC. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine 2014; 68(2):101-9; PMID:24767864; https://doi.org/10.1016/j.cyto.2014.04.001
81. Simpson JL, Baines KJ, Boyle MJ, Scott RJ, Gibson PG. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res 2009; 35(9):781-94; PMID:19916861; https://doi.org/10.3109/01902140902906412
82. Kang HJ, Kang JS, Lee SH, Hwang SJ, Chae SW, Woo JS, Lee HM. Upregulation of oncostatin m in allergic rhinitis. Laryngoscope 2005; 115(12):2213-6; PMID:16369169; https://doi.org/10.1097/01.mlg.0000187819.89889.4a
83. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, Garcia M, Venereau E, Preisser L, Guignouard E, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007; 178(7):4615-22; https://doi.org/10.4049/jimmunol.178.7.4615
84. Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, Harris KE, Shintani-Smith S, Conley DB, Chandra RK, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol 2015; 136(3):737-46 e4; https://doi.org/10.1016/j.jaci.2015.01.043
85. Pothoven KL, Norton JE, Suh LA, Carter RG, Harris KE, Biyasheva A, Welch K, Shintani-Smith S, Conley DB, Liu MC, et al. Neutrophils are a major source of the epithelial barrier disrupting cytokine Oncostatin M in patients with mucosal airways disease. J Allergy Clin Immunol, 2017; 139(6):p. 1966-1978 e9.
86. Fritz DK, Kerr C, Fattouh R, Llop-Guevara A, Khan WI, Jordana M, Richards CD. A mouse model of airway disease:oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. J Immunol 2011; 186(2):1107-18; https://doi.org/10.4049/jimmunol.0903476
87. Botelho FM, Rangel-Moreno J, Fritz D, Randall TD, Xing Z, Richards CD. Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation. J Immunol 2013; 191(3):1453-64; https://doi.org/10.4049/jimmunol.1203318
88. Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, Blumenberg M. A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol 2006; 126(12):2647-57; PMID:16917497; https://doi.org/10.1038/sj.jid.5700461
89. Lin YZ, Li RN, Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH. Association of OSMR gene polymorphisms with rheumatoid arthritis and systemic lupus erythematosus patients. Autoimmunity 2014; 47(1):23-6; PMID:24219225; https://doi.org/10.3109/08916934.2013.849701
90. Hong IK, Eun YG, Chung DH, Kwon KH, Kim DY. Association of the oncostatin m receptor gene polymorphisms with papillary thyroid cancer in the korean population. Clin Exp Otorhinolaryngol 2011; 4(4):193-8; PMID:22232715; https://doi.org/10.3342/ceo.2011.4.4.193
91. Matzinger P, Kamala T. Tissue-based class control:the other side of tolerance. Nat Rev Immunol 2011; 11(3):221-30; PMID:21350581; https://doi.org/10.1038/nri2940
92. Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol 1987; 138(12):4515-23
93. Linthicum DS, Mackay IR, Carnegie PR. Measurement of cell-mediated inflammation in experimental murine autoimmune encephalomyelitis by radioisotopic labeling. J Immunol 1979; 123(4):1799-805
94. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 1992; 22(1):165-73; PMID:1530916; https://doi.org/10.1002/eji.1830220125
95. Kosiewicz MM, Alard P, Streilein JW. Alterations in cytokine production following intraocular injection of soluble protein antigen:impairment in IFN-gamma and induction of TGF-beta and IL-4 production. J Immunol 1998; 161(10):5382-90
96. Jankowski R, Bouchoua F, Coffinet L, Vignaud JM. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology 2002; 40(4):173-8; PMID:12526243
97. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, Lin P, Bousquet J, Van Steen K. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol 2010; 126(5):962-8, 8 e1-6; PMID:20810157; https://doi.org/10.1016/j.jaci.2010.07.007
98. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, Wang DY, Desrosiers M, Liu Z. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol 2009; 124(3):478-84, 84 e1-2; PMID:19541359; https://doi.org/10.1016/j.jaci.2009.05.017
99. Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, Luo Q, Zheng J, Wang H, Li Z, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol 2012; 129(6):1522-8 e5; PMID:22460066; https://doi.org/10.1016/j.jaci.2012.01.079
100. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respiratory Critical Care Med 1999; 160(5 Pt 1):1532-9; PMID:10556116; https://doi.org/10.1164/ajrccm.160.5.9806170
101. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma:evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119(5):1329-36; https://doi.org/10.1378/chest.119.5.1329
102. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373(9678):1905-17; https://doi.org/10.1016/S0140-6736(09)60326-3
103. Grenier A, Combaux D, Chastre J, Gougerot-Pocidalo MA, Gibert C, Dehoux M, Chollet-Martin S. Oncostatin M production by blood and alveolar neutrophils during acute lung injury. Lab Invest 2001; 81(2):133-41; PMID:11232634; https://doi.org/10.1038/labinvest.3780220
104. Cross A, Edwards SW, Bucknall RC, Moots RJ. Secretion of oncostatin M by neutrophils in rheumatoid arthritis. Arthritis Rheum 2004; 50(5):1430-6; PMID:15146412; https://doi.org/10.1002/art.20166
105. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M:potential implications for tumor progression. Cancer Res 2005; 65(19):8896-904; PMID:16204061; https://doi.org/10.1158/0008-5472.CAN-05-1734
106. Su CM, Chiang YC, Huang CY, Hsu CJ, Fong YC, Tang CH. Osteopontin Promotes Oncostatin M production in human osteoblasts:Implication of rheumatoid arthritis therapy. J Immunol 2015; 195(7):3355-64; https://doi.org/10.4049/jimmunol.1403191
107. Kastl SP, Speidl WS, Kaun C, Katsaros KM, Rega G, Afonyushkin T, Bochkov VN, Valent P, Assadian A, Hagmueller GW, et al. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler Thromb Vasc Biol 2008; 28(3):498-503; PMID:18187666; https://doi.org/10.1161/ATVBAHA.107.160580
108. Repovic P, Benveniste EN. Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microglia. J Neurosci 2002; 22(13):5334-43; PMID:12097485
109. Miller M, Beppu A, Rosenthal P, Pham A, Das S, Karta M, Song DJ, Vuong C, Doherty T, Croft M, et al. Fstl1 promotes asthmatic airway remodeling by inducing oncostatin M. J Immunol 2015; 195(8):3546-56; https://doi.org/10.4049/jimmunol.1501105
110. Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages:a link between coagulation and inflammation. Blood 2009; 114(13):2812-8; PMID:19652200; https://doi.org/10.1182/blood-2009-01-200915
111. Elbjeirami WM, Donnachie EM, Burns AR, Smith CW. Endothelium-derived GM-CSF influences expression of oncostatin M. Am J Physiol Cell Physiol 2011; 301(4):C947-53; PMID:21775705; https://doi.org/10.1152/ajpcell.00205.2011
112. Ohno I, Lea R, Finotto S, Marshall J, Denburg J, Dolovich J, Gauldie J, Jordana M. Granulocyte/macrophage colony-stimulating factor (GM-CSF) gene expression by eosinophils in nasal polyposis. Am J Respiratory Cell Mol Biol 1991; 5(6):505-10; PMID:1958376; https://doi.org/10.1165/ajrcmb/5.6.505
113. Kato M, Liu MC, Stealey BA, Friedman B, Lichtenstein LM, Permutt S, Schleimer RP. Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects. Lymphokine Cytokine Res 1992; 11(6):287-92; PMID:1477181
114. Miller M, Esnault S, Kurten RC, Kelly EA, Beppu A, Das S, Rosenthal P, Ramsdell J, Croft M, Zuraw B, et al. Segmental allergen challenge increases levels of airway follistatin-like 1 in patients with asthma. J Allergy Clin Immunol 2016; 138(2):596-599.e4; https://doi.org/10.1016/j.jaci.2016.01.019
115. Anwar AR, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993; 177(3):839-43; PMID:8436913; https://doi.org/10.1084/jem.177.3.839
116. Durand V, Renaudineau Y, Pers JO, Youinou P, Jamin C. Cross-linking of human FcgammaRIIIb induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils. J Immunol 2001; 167(7):3996-4007; https://doi.org/10.4049/jimmunol.167.7.3996
117. Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, Zhou J, Norton J, Carter R, Hinchcliff M, et al. Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2011; 128(6):1198-206 e1; https://doi.org/10.1016/j.jaci.2011.08.037
118. Engelhardt E, Toksoy A, Goebeler M, Debus S, Brocker EB, Gillitzer R. Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol 1998; 153(6):1849-60; PMID:9846975; https://doi.org/10.1016/S0002-9440(10)65699-4
119. Goren I, Kampfer H, Muller E, Schiefelbein D, Pfeilschifter J, Frank S. Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair:implications for normal and diabetes-impaired wounds. J Invest Dermatol 2006; 126(3):628-37; PMID:16410783; https://doi.org/10.1038/sj.jid.5700136
120. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta:“N1” versus “N2” TAN. Cancer Cell 2009; 16(3):183-94; PMID:19732719; https://doi.org/10.1016/j.ccr.2009.06.017
121. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 2013; 62(11):1745-56; PMID:24092389; https://doi.org/10.1007/s00262-013-1476-9
122. Ma Y, Yabluchanskiy A, Iyer RP, Cannon PL, Flynn ER, Jung M, Henry J, Cates CA, Deleon-Pennell KY, Lindsey ML. Temporal neutrophil polarization following myocardial infarction. Cardiovasc Res 2016; 110(1):51-61; PMID:26825554; https://doi.org/10.1093/cvr/cvw024
123. Cuartero MI, Ballesteros I, Moraga A, Nombela F, Vivancos J, Hamilton JA, Corbí, ÁL, Lizasoain I, Moro MA. N2 neutrophils, novel players in brain inflammation after stroke:modulation by the PPARgamma agonist rosiglitazone. Stroke 2013; 44(12):3498-508; PMID:24135932; https://doi.org/10.1161/STROKEAHA.113.002470
124. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, Ding JL. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 2013; 93(7):844-54; PMID:23752129; https://doi.org/10.1038/labinvest.2013.69
125. Nightingale J, Patel S, Suzuki N, Buxton R, Takagi KI, Suzuki J, Sumi Y, Imaizumi A, Mason RM, Zhang Z. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Society Nephrology 2004; 15(1):21-32; PMID:14694154; https://doi.org/10.1097/01.ASN.0000102479.92582.43
126. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Ann Rev Path 2017. 12:p. 331-357.
127. West NR, Murphy LC, Watson PH. Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer 2012; 19(2):181-95; PMID:22267707; https://doi.org/10.1530/ERC-11-0326
128. West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2014; 33(12):1485-94; PMID:23584474; https://doi.org/10.1038/onc.2013.105
129. Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, Anderson R, Jorcyk CL. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer 2012; 3(2):117-30; PMID:23050044; https://doi.org/10.1177/1947601912458284
130. Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E, Quintanilla M, et al. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Br J Cancer 2016; 115(2):212-22; PMID:27351213; https://doi.org/10.1038/bjc.2016.199
131. Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, Kaur H, Bhatt ML, Bhadauria S. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 2014; 5(14):5350-68; PMID:25051364; https://doi.org/10.18632/oncotarget.2110
132. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9:216; PMID:22176642; https://doi.org/10.1186/1479-5876-9-216
133. Uribe-Querol E, Rosales C. Neutrophils in cancer:Two sides of the same coin. J Immunol Res 2015; 2015:983698; PMID:26819959; https://doi.org/10.1155/2015/983698
134. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007; 204(5):1037-47; PMID:17438063; https://doi.org/10.1084/jem.20061120
135. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208(3):469-78; PMID:21339327; https://doi.org/10.1084/jem.20101876
136. Lo Kuan E, Ziegler SF. Thymic stromal lymphopoietin and cancer. J Immunol 2014; 193(9):4283-8; https://doi.org/10.4049/jimmunol.1400864
137. Liu X, Hemminki K, Forsti A, Sundquist J, Sundquist K, Ji J. Cancer risk and mortality in asthma patients:A Swedish national cohort study. Acta Oncol 2015; 54(8):1120-7; PMID:25608824; https://doi.org/10.3109/0284186X.2014.1001497
138. Santillan AA, Camargo CA, Jr, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003; 14(4):327-34; PMID:12846363; https://doi.org/10.1023/A:1023982402137
139. Eriksson NE, Holmen A, Hogstedt B, Mikoczy Z, Hagmar L. A prospective study of cancer incidence in a cohort examined for allergy. Allergy 1995; 50(9):718-22; PMID:8546265; https://doi.org/10.1111/j.1398-9995.1995.tb01212.x
140. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6):1420-8; PMID:19487818; https://doi.org/10.1172/JCI39104
141. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112(12):1776-84; PMID:14679171; https://doi.org/10.1172/JCI200320530
142. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119(6):1429-37; PMID:19487819; https://doi.org/10.1172/JCI36183
143. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273(4 Pt 2):F563-74; PMID:9362334
144. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70; PMID:10647931; https://doi.org/10.1016/S0092-8674(00)81683-9
145. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002; 61(5):1714-28; PMID:11967021; https://doi.org/10.1046/j.1523-1755.2002.00333.x
146. Yang J, Weinberg RA. Epithelial-mesenchymal transition:at the crossroads of development and tumor metastasis. Dev Cell 2008; 14(6):818-29; PMID:18539112; https://doi.org/10.1016/j.devcel.2008.05.009
147. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015; 519(7541):57-62; PMID:25731159; https://doi.org/10.1038/nature14228
148. Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci 2012; 125(Pt 19):4417-22; PMID:23165231; https://doi.org/10.1242/jcs.099697
149. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28(1–2):15-33; PMID:19169796; https://doi.org/10.1007/s10555-008-9169-0
150. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci 2008; 121(Pt 6):727-35; PMID:18322269; https://doi.org/10.1242/jcs.000455
151. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E. Defining the epithelial stem cell niche in skin. Science 2004; 303(5656):359-63; PMID:14671312; https://doi.org/10.1126/science.1092436
152. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006; 131(5):1486-500; PMID:17101323; https://doi.org/10.1053/j.gastro.2006.08.041
153. Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell 2011; 22(24):4750-64; PMID:22031288; https://doi.org/10.1091/mbc.E11-02-0119
154. Orimo A, Weinberg RA. Stromal fibroblasts in cancer:a novel tumor-promoting cell type. Cell Cycle 2006; 5(15):1597-601; PMID:16880743; https://doi.org/10.4161/cc.5.15.3112
155. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005; 233(3):706-20; PMID:15937929; https://doi.org/10.1002/dvdy.20345
156. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010; 24(6):1838-51; PMID:20097873; https://doi.org/10.1096/fj.09-151639
157. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF. Epithelial to mesenchymal transition during late deterioration of human kidney transplants:the role of tubular cells in fibrogenesis. Am J Transplant 2005; 5(6):1367-74; PMID:15888043; https://doi.org/10.1111/j.1600-6143.2005.00843.x
158. Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition. Matrix Biol 2011; 30(4):243-7; PMID:21477649; https://doi.org/10.1016/j.matbio.2011.03.007
159. Szell M, Bata-Csorgo Z, Koreck A, Pivarcsi A, Polyanka H, Szeg C, Gaál M, Dobozy A, Kemény L. Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J Invest Dermatol 2004; 123(3):537-46; PMID:15304094; https://doi.org/10.1111/j.0022-202X.2004.23224.x
160. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15(3):178-96; PMID:24556840; https://doi.org/10.1038/nrm3758
161. Choy EH, Bendit M, McAleer D, Liu F, Feeney M, Brett S, Zamuner S, Campanile A, Toso J. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis:results from phase II randomized, placebo-controlled trials. Arthritis Res Therapy 2013; 15(5):R132; https://doi.org/10.1186/ar4312
162. Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol 2013; 174(3):356-63; PMID:23968543; https://doi.org/10.1111/cei.12190
163. Brolund L, Kuster A, Korr S, Vogt M, Muller-Newen G. A receptor fusion protein for the inhibition of murine oncostatin M. BMC Biotechnol 2011; 11:3; PMID:21223559; https://doi.org/10.1186/1472-6750-11-3
164. Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis:results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015; 74(6):1058-64; PMID:24534756; https://doi.org/10.1136/annrheumdis-2013-204816
165. Molfino NA, Kuna P, Leff JA, Oh CK, Singh D, Chernow M, Sutton B, Yarranton G. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open 2016; 6(1):e007709; PMID:26739717; https://doi.org/10.1136/bmjopen-2015-007709
166. Takeuchi T, Tanaka Y, Close D, Godwood A, Wu CY, Saurigny D. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis:findings from a Phase IIa study. Mod Rheumatol 2015; 25(1):21-30; PMID:24720551; https://doi.org/10.3109/14397595.2014.896448
167. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72(9):1445-52; PMID:23234647; https://doi.org/10.1136/annrheumdis-2012-202450